武汉佰乐博代理：Research Grade Telisotuzumab
货号：DHC34203
产品链接：http://www.atagenix.com/product_detail-75316.html
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
产品介绍：Telisotuzumab (ABT-700)是一种人源化重组二价抗体，针对肝细胞生长因子受体（MET）的治疗性抗体，可以高亲和力结合c-Met并抑制c-Met信号传导。Telisotuzumab具有抗肿瘤活性。
通用名：Telisotuzumab
纯度：>95% by SDS-PAGE.
浓度：1mg/ml
Formulationicon：0.01M PBS, pH 7.4.
内毒素：Please contact with the lab for this information.
别名：ABBV-399, ABT-700-vcMMAE, ABT-700, hz224G11
靶点;物种：Human MET/c-Met/HGFR
种类：Humanized
受体鉴定：IgG1-kappa
CAS: 1781223-80-0
参考文献：
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). PMID: 33221175
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. PMID: 36288547
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. PMID: 33675179
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. PMID: 35005654
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. PMID: 30285518
